Related references
Note: Only part of the references are listed.STAT1: A Novel Target of miR-150 and miR-223 Is Involved in the Proliferation of HTLV-I-Transformed and ATL Cells
Ramona Moles et al.
NEOPLASIA (2015)
MiR-221 accentuates IFN's anti-HCV effect by downregulating SOCS1 and SOCS3
Gang Xu et al.
VIROLOGY (2014)
The evolving genomic landscape of myeloproliferative neoplasms
Jyoti Nangalia et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)
MicroRNAs in myeloproliferative neoplasms
Huichun Zhan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Methylation profiling of SOCS1, SOCS2, SOCS3, CISH and SHP1 in Philadelphia-negative myeloproliferative neoplasm
Min Yue Zhang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2013)
Acute myeloid leukemia with translocation (8:16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene
M. Diaz-Beya et al.
LEUKEMIA (2013)
MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemia
Gerardo Ferrer et al.
LEUKEMIA & LYMPHOMA (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
MECHANISMS OF DISEASE JAKs and STATs in Immunity, Immunodeficiency, and Cancer
John J. O'Shea et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Systematic analysis of microRNA fingerprints in thrombocythemic platelets using integrated platforms
Xiao Xu et al.
BLOOD (2012)
DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways
Ioannis S. Vlachos et al.
NUCLEIC ACIDS RESEARCH (2012)
New mutations and pathogenesis of myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2011)
Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia
Juan-Carlos Hernandez-Boluda et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Porphyromonas gingivalis Induction of MicroRNA-203 Expression Controls Suppressor of Cytokine Signaling 3 in Gingival Epithelial Cells
Catherine E. Moffatt et al.
INFECTION AND IMMUNITY (2011)
Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation
S. Barrio et al.
JOURNAL OF CLINICAL PATHOLOGY (2011)
miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets
Michael Girardot et al.
BLOOD (2010)
Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma
Alfons Navarro et al.
BLOOD (2009)
MicroRNAs: Target Recognition and Regulatory Functions
David P. Bartel
CELL (2009)
Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression
Maria J. Bueno et al.
CANCER CELL (2008)
MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors
Jun Lu et al.
DEVELOPMENTAL CELL (2008)
Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders
Nasios Fourouclas et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases
Luciana Teofili et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science
O. Kilpivaara et al.
LEUKEMIA (2008)
MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications
M. Fabbri et al.
LEUKEMIA (2008)
JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders:: advantage of studying platelets
Kohtaro Toyama et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis
B. Bellosillo et al.
LEUKEMIA (2007)
Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders
E. Jost et al.
LEUKEMIA (2007)
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Ross L. Levine et al.
NATURE REVIEWS CANCER (2007)
Mechanisms of disease: The myeloproliferative disorders
Peter J. Campbell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
MicroRNAs modulate hematopoietic lineage differentiation
CZ Chen et al.
SCIENCE (2004)
The World Health Organization (WHO) classification of the myeloid neoplasms
JW Vardiman et al.
BLOOD (2002)
Share Paper
